Private Equity
Steve Case speaks about crowdfunding, entrepreneurship and what should guide the missions of the next generation of startup leaders with Reuters digital editor Lawrence Aragon at Venture Alpha 2012.
2 min read · 19 October 2012
APIM Therapeutics, a preclinical biotech company targeting cancer therapeutics, has closed a new round to continue drug development. Investors included Norsk Innovasjonskapital III AS, Birk Venture and Sarsia Seed.
2 min read · 18 October 2012
It isn't private equity firms that ought to be reaping bigger balance sheets from some of the smallest investors. If life sciences & biotech venture capitalists are to make it through industry-wide consolidation, they should have access to a new class of capital. How about 401(k)s?
3 min read · 17 October 2012
Rumors swirled Monday that e-commerce titan Amazon is looking to acquire processing capabilities from Texas Instruments that signal a one-way transition into the tablet and handset space. However, the Washington-based company has a lot of M&A to undertake if it wants to truly compete with Google, Apple and Samsung.
3 min read · 15 October 2012
The Renaissance Venture Capital Fund is aiming to close a second fund of up to $75 million, peHUB has learned, as the VC fund-of-funds plans to deploy more capital for—of all things—life sciences VCs.
2 min read · 15 October 2012
What's on readers' minds at peHUB? Fundraising, the latest deals and the Carlyle Group, it seems. This week's wrapup has the latest on what you want.
1 min read · 14 October 2012
For a very special Friday First Read, we've got the preview for this afternoon's rumble in the Bronx, debate results and Bain's big deal.
1 min read · 12 October 2012
David Rubenstein, co-founder and co-CEO of the Carlyle Group, sat down this week for an interview with our friends at Reuters TV. Here were some takeaways from a spirited discussion.
3 min read · 10 October 2012
Peter Gudwin has joined HIG Capital as an associate. He will be based in New York City. Gudwin previously worked as a vice president with JH Whitney, and also as an associate at the Blackstone Group.
1 min read · 09 October 2012
Boston Scientific, the listed medical device company, announced it will spend $90 million up front and as much as a whopping $175 million more in milestone payments over the next five years to acquire Rhythmia Medical, a Massachusetts startup treats cardiac arrhythmia. And, paid in full, that will result in a whopping exit of more than 16x for VCs and entrepreneurs who dedicated their last eight years and about $16.5 million to the company.
2 min read · 09 October 2012
